1 recruiting, 1 withdrawn. 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Wee1 Inhibitor ZN-c3: new trials by email Literature Review of Wee1 Inhibitor ZN-c3 trials Research Report on Wee1 Inhibitor ZN-c3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-19 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 |
Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (1)
Evthokia Hobbs, M.D. (1) · Funda Meric-Bernstam (1)
UM1CA186688 (1)